Many myths persist about the connection between’s dairy consumption and the increased risk of breast cancer. Over the last decades, various studies have indicated that dairy utilization doesn’t involve the danger of breast cancer.
But a new study published in the journal International Journal of Epidemiology finds that there are more chances to develop breast cancer in those women who drink milk daily.
This study has followed more than fifty thousand women in North America. And the study’s author Dr. Gary Fraser tells that the risk of developing breast cancer goes up to fifty percent in those women who drink a cup of milk daily.
While this risk increases up to seventy percent or eighty percent in those women who drink two or three cups of milk daily. Researchers also find that soy products are not associated with the elevated risks of breast cancer.
Also, the study does not take into account other risk factors for breast cancer, including environment, ethnicity, family history, and genetic testing. Before the finish of the examination time frame, there were more than ten thousand cases during development.
No reasonable affiliations were found between soy items and breast cancer, free of dairy. Be that as it may, when contrasted with low or no milk utilization, higher admissions of dairy calories and dairy milk were related to more danger of breast malignant growth, free of soy consumption.
And the potential explanations behind these relationships between breast cancer and dairy milk might be the sex hormone substance of dairy milk, as the bovines are lactating, and frequently about 75% of the dairy group is pregnant. And in women is a hormone-responsive disease.
Fraser noticed that the outcomes had negligible variety when contrasting admission of full fat versus decreased or nonfat milk; there were no significant affiliations noted with cheddar and yogurt.
In the present study, more than ten thousand women are diagnosed with breast cancer or two percent of the total women. Presently the American women are at risk of thirteen percent to develop breast cancer at some point during their lives.
The American Cancer Society (ACS) estimates that more than forty thousand women will die from breast cancer this year. It’s the subsequent driving reason for cancer death in women behind lung malignant growth and the American Cancer Society (ACS) estimates that more than sixty thousand women will succumb in 2020.
Breast cancer patients may find another option soon
A biotech company Seattle Genetics (NASDAQ: SGEN) is trying to bring a new breast cancer drug to market that is tucatinib. HER2-positive breast cancer is a destructive form of cancer that grows and divides rapidly but can be treated by this new drug, tucatinib.
One of every five breast malignant growths fall into this grouping. Seattle Genetics applied for another medication application toward the end of last year, and the Food and Drug Administration declared not long ago that it has allowed the drug a priority review.